Medical Oncology

Vasculitis

Questions discussed in this category

Is IL-6 inhibition an option in patients who are going to be rechallenged with checkpoint inhibitors after previously developing ICI-mediated temporal arteritis?

Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?

2 Answers available

How would you approach the treatment of checkpoint-inhibitor-mediated temporal arteritis?

Is there role for IVIG? Would you alter the dose or time course of steroid therapy?

2 Answers available

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?

2 Answers available

How do you manage incidentally identified chemotherapy-associated aortitis/large vessel vasculitis?

1 Answer available

Papers discussed in this category

BJR Case Rep, 2018 Sep 08

A case of aortitis during cisplatin-based chemotherapy for cervical cancer.

JAMA network open, 2018-11-02

Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia.

Eur J Cancer, 2021 Sep 15

Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.

Thorac Cancer, 2020 Feb 11

The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).

Related Topics in Medical Oncology